APTIOM®

Drug Information Related Patent
Hold Company
SUMITOMO PHARMA AM
Learn More
Dosage and Administration
TABLET;ORAL
Specification
200MG; 400MG; 600MG; 800MG
Indication
APTIOM® is indicated for the treatment of partial-onset epilepsy in patients 4 years of age and older.
Use
Instructions for Use
API
ESLICARBAZEPINE ACETATE
API Structure
We Supply
ESLICARBAZEPINE ACETATE
Note:

In-house Standard
Facility GMP
USMF/DMF in processing

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
106752872025/5/6
106953542025/5/6
107025362025/5/6
109127812028/10/23
113642472025/5/6
83724312030/4/17
92061352026/4/21
95662442028/10/23
96439292026/4/21
97507472032/8/24
97639542028/9/13
API Patent
Patent NoExpiration Date
92061352026/4/21
96439292026/4/21
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
dcat
Member of
dcat
Top